SHANGHAI, Aug. 12 (Xinhua) -- The Shiseido Beauty Innovations Fund announced its first investment to a Chinese biomaterial maker Jiangsu Trautec Medical Technology Co., Ltd (Trautec) on Wednesday.
Shiseido China will act as lead investor with an amout close to 100 million yuan (about 14.83 million U.S. dollars) in the investment, which is expected to invest in Trautec’s series A round of funding, according to a company website release of Shiseido China Co., Ltd.
Jointly launched by Shiseido China and an investment firm Boyu Capital, the Shiseido Beauty Innovations Fund will focus on beauty industry and explore investment opportunities among China’s emerging companies in cosmetics and wellness, as well as in related technology companies such as e-commerce and digital services.
By investing in Trautec, Shiseido China aims to integrate the resources of both parties in areas such as product research and development (R&D), raw material supply, and sales channels to accelerate the exploration of new areas in functional skincare, which is related to sensitive skin, aging care and clean beauty.
Shiseido China CEO Kentaro Fujiwara expressed his confidence in Chinese market, saying that deeply committed to the Chinese market for over 40 years, Shiseido has always believed in the great potential of Chinese market and continuously invested in China. The launch of the Shiseido Beauty Innovations Fund is a case in point.
He added that the partnership with Trautec helps Shiseido to step into the promising field of functional skincare in China. With Shiseido’s experience in brand management and R&D, the two sides will contribute together to the high-quality development of China’s beauty industry.
"The investment is a strong endorsement of Trautec and will fuel Trautec’s innovation and entry into international markets," said Qian Song, CEO of Trautec. With Shiseido’s management experience and its vast global network, the firm hopes to promote its products to a larger international audience.
Qian noted that the two sides will work together to seize the vast opportunities in recombinant collagen technology and strive to make China a world leader in the field.
Photo shows the staff of Trautec doing cosmetic research. [Photo provided by Trautec]
Established in 2015, Trautec is dedicated to the development and production of recombinant collagen*2-based biomaterials for mainly medical and cosmetics industries. Trautec operates the full value chain from R＆D, manufacturing, to distribution, by holding multiple intellectual property rights in the development of recombinant collagen, and owning its production plant located in Changzhou, east China's Jiangsu Province.
(Contributed by Hu Jiefei in Shanghai, edited by Li Shimeng with Xinhua Silk Road, lishimeng@xinhua.org)
A single purchase
